A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage.

被引：14
|
作者：
Tamberi, Stefano
Grassi, Elisa
Corbelli, Jody
Papiani, Giorgio
Barbera, Maria Aurelia
Zingaretti, Chiara
Moretti, Chiara Carli
Montroni, Isacco
Petracci, Elisabetta
Caruso, Dora
Nosseir, Sofia
Nanni, Oriana
Frassineti, Giovanni Luca
Di Bartolomeo, Maria
Marzola, Marina
Bonetti, Andrea
Gelsomino, Fabio
Pinto, Carmine
Tassinari, Davide
Ugolini, Giampaolo
机构：
[1] Ospedale Gli Infermi, Faenza, Italy
[2] Infermi Hosp, Faenza, Italy
[3] IRCCS, IRST Meldola, Unita Biostat & Sperimentazioni Clin, Ravenna, Italy
[4] Infermi Hosp, Faenza, Italy
[5] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Biostat & Clin Trials, Meldola, Italy
[6] Ravenna Hosp, Dept Pathol, Ravenna, Italy
[7] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCSS, Meldola, Italy
[8] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCSS, Med Oncol Unit, Meldola, Italy
[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[10] Univ Ferrara, Ferrara, Italy
[11] Mater Salutis Hosp, Dept Med Oncol, Legnago, Italy
[12] Univ Hosp Modena, Modena, Italy
[13] AUSL IRCCS Reggio Emilia, Med Oncol Unit, Clin Canc Ctr, Reggio Emilia, Italy
[14] Dept Oncol, Rimini, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3607
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)
    Ishii, Hidenobu
    Azuma, Koichi
    Shimose, Takayuki
    Yoshioka, Hiroshige
    Kurata, Takayasu
    Shingu, Naoki
    Okamoto, Masaki
    Kawashima, Yosuke
    Okamoto, Isamu
    THORACIC CANCER, 2023, 14 (01) : 105 - 107
  • [22] Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer:: a multicentric phase II study
    De Paoli, A
    Chiara, S
    Luppi, G
    Friso, ML
    Beretta, GD
    Del Prete, S
    Pasetto, L
    Santantonio, M
    Sarti, E
    Mantello, G
    Innocente, R
    Frustaci, S
    Corvò, R
    Rosso, R
    ANNALS OF ONCOLOGY, 2006, 17 (02) : 246 - 251
  • [23] Oxaliplatin plus capecitabine in combination with radiation therapy for treatment of cervical cancer: A phase II study
    Levine, L.
    Hatch, S.
    Richardson, G.
    Robinson-Bennett, B.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S38 - S39
  • [24] A PHASE II STUDY OF CHECK POINT INHIBITOR, DURVALUMAB (MEDI4736) FOR BACILLUS CALMETTE-GUERIN UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER
    Li, Roger
    Rose, Kyle
    Poch, Michael
    Spiess, Philippe
    Gilbert, Scott
    Sexton, Wade
    Zhang, Jingsong
    JOURNAL OF UROLOGY, 2022, 207 (05): : E927 - E927
  • [25] Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) plus tremelimumab (TRE) in patients with advanced solid tumors.
    Callahan, Margaret K.
    Odunsi, Kunle
    Sznol, Mario
    Nemunaitis, John J.
    Ott, Patrick Alexander
    Dillon, Patrick Michael
    Park, Andrew J.
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary J.
    Ryan, Aileen
    Venhaus, Ralph Rudolph
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study
    Mamdani, Hirva
    Kim, Seongho
    Gentzler, Ryan D.
    Shields, Misty Dawn
    Furqan, Muhammad
    Pizana, Kristen
    Abid, Qura
    Jalal, Shadia Ibrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer
    Rimel, B. J.
    Bender, David
    Enserro, Danielle
    Westin, Shannon Neville
    Richardson, Debra L.
    Holman, Laura L.
    Alluri, Nitya
    Stuckey, Ashley
    Garg, Ruchi
    Gill, Sarah
    Tanner, Edward
    Leath, Charles A.
    Backes, Floor Jenniskens
    Fleury, Aimee
    Mackay, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.
    Kato, Yuka
    Ohashi, Kadoaki
    Kozuki, Toshiyuki
    Kuyama, Shoichi
    Yamaguchi, Kakuhiro
    Yokoyama, Toshihide
    Uno, Hideki
    Yoshida, Michihiro
    Hattori, Noboru
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: The NIBIT-MESO-1 study.
    Calabrao, Luana
    Morra, Aldo
    Giannarelli, Diana
    Annesi, Diego
    Bertocci, Erica
    Danielli, Riccardo
    Altomonte, Maresa
    Di Giacomo, Anna Maria
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
    Jo, Hyunji
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Yu, Jeong Il
    Park, Hee Chul
    Choi, Doo Ho
    Park, Yoonah
    Cho, Yong Beom
    Huh, Jung Wook
    Yun, Seong Hyeon
    Kim, Hee Cheol
    Lee, Woo Yong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 189 - 195
12345